Investors Who Bought Mirati Therapeutics (NASDAQ:MRTX) Shares Five Years Ago Are Now Up 932%
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality companies can see their share prices grow by huge amounts. To wit, the Mirati Therapeutics, Inc. (NASDAQ:MRTX) share price has soared 932% over five years. This just goes to show the value creation that some businesses can achieve. Meanwhile the share price is 1.1% higher than it was a week ago.
Anyone who held for that rewarding ride would probably be keen to talk about it.
Check out our latest analysis for Mirati Therapeutics
Mirati Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
Mirati Therapeutics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. If you are thinking of buying or selling Mirati Therapeutics stock, you should check out this free report showing analyst consensus estimates for future profits.
A Different Perspective
We're pleased to report that Mirati Therapeutics shareholders have received a total shareholder return of 124% over one year. That gain is better than the annual TSR over five years, which is 59%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 3 warning signs for Mirati Therapeutics that you should be aware of.
We will like Mirati Therapeutics better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
